Guangzhou LBP Medicine Science & Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
April 27, 2021 at 02:37 pm IST
Share
Guangzhou LBP Medicine Science & Technology Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 99.508 million compared to CNY 38.461 million a year ago. Operating income was CNY 31.303 million compared to CNY 10.729 million a year ago. Net income was CNY 26.664 million compared to CNY 9.880 million a year ago. Basic earnings per share from continuing operations was CNY 0.29 compared to CNY 0.14 a year ago.
Guangzhou LBP Medicine Science & Technology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of in vitro diagnostic reagents and instruments. The Companyâs main products are pathological diagnostic reagents and instruments, covering three major technology platforms for cytological diagnosis, molecular diagnosis and immunodiagnosis, including LBP series, IHC series, PCR series and FISH series, such as integrated slide and dyeing machine, liquid-based cell and microorganism processing, preservation reagents, automatic nucleic acid molecular hybridization instrument, automatic slide processing system and immunochromogenic reagents, etc. Its products are mainly used in pathological diagnosis of tumors. The Company operates its businesses within the domestic market and to overseas markets.